Compare TILE & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TILE | ANAB |
|---|---|---|
| Founded | 1973 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Home Furnishings | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.3B |
| IPO Year | 1994 | 2015 |
| Metric | TILE | ANAB |
|---|---|---|
| Price | $28.89 | $50.76 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 1 | 12 |
| Target Price | $36.00 | ★ $71.67 |
| AVG Volume (30 Days) | 517.8K | ★ 559.1K |
| Earning Date | 05-08-2026 | 05-08-2026 |
| Dividend Yield | ★ 0.29% | N/A |
| EPS Growth | 32.43 | ★ 91.02 |
| EPS | ★ 0.40 | N/A |
| Revenue | ★ $1,386,854,000.00 | $234,603,000.00 |
| Revenue This Year | $6.72 | N/A |
| Revenue Next Year | $5.61 | $52.14 |
| P/E Ratio | $71.95 | ★ N/A |
| Revenue Growth | 5.41 | ★ 157.01 |
| 52 Week Low | $20.01 | $17.11 |
| 52 Week High | $35.11 | $73.30 |
| Indicator | TILE | ANAB |
|---|---|---|
| Relative Strength Index (RSI) | 52.05 | 29.84 |
| Support Level | $26.60 | $43.75 |
| Resistance Level | $28.89 | $51.67 |
| Average True Range (ATR) | 1.02 | 2.93 |
| MACD | -0.02 | -1.23 |
| Stochastic Oscillator | 58.14 | 1.45 |
Interface Inc is engaged in the design, production, and sale of carpet tiles. It also provides Luxury Vinyl tiles and rubber flooring. The company mainly targets corporate and noncorporate office markets, including government, education, healthcare, hospitality, and retailers. Its geographical segments include the Americas, Europe, and Asia-Pacific. It has two operating and reportable segments- namely Americas (AMS) and Europe, Africa, Asia and Australia (collectively EAAA). Key revenue is generated from AMS segment. Its products include: ESD, Acoustic, Extreme Wear, and Quick Installation System (nTx).
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).